<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835393</url>
  </required_header>
  <id_info>
    <org_study_id>B036582</org_study_id>
    <nct_id>NCT00835393</nct_id>
  </id_info>
  <brief_title>Pantoprazole Sodium 40 mg DR Tablets Under Non-Fasting Conditions</brief_title>
  <official_title>A Relative Bioavailability Replicated Crossover Study of Pantoprazole Sodium 40 mg DR Tablets Under Non-Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Objective of this study is to compare the relative bioavailability of pantoprazole sodium&#xD;
      40 mg delayed-released tablets (manufactured by TEVA Pharmaceutical Industries,Ltd. and&#xD;
      distributed by TEVA Pharmaceuticals USA)with that of PROTONIX® 40mg delayed-released tablets&#xD;
      (Wyeth- Ayerst) in Healthy, adult, non-smoking subjects under non- fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole Sodium 40 mg delayed-release tablets</intervention_name>
    <description>1 x 40 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PROTONIX® 40 mg delayed-release tablets.</intervention_name>
    <description>1 x 40 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects selected for this study will be non-smokers at least 18 years of age.&#xD;
             Subjects will have a BMI (Body Mass Index) of 30 or less.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a significant recent history of chronic alcohol consumption (past 2&#xD;
             years), drug addiction, or serious gastrointestinal, renal, hepatic or cardiovascular,&#xD;
             disease, tuberculosis, epilepsy, asthma (past 5 years), diabetes, psychosis or&#xD;
             glaucoma will not be eligible for this study.&#xD;
&#xD;
          -  Subjects whose clinical laboratory test values are greater than 20% outside the normal&#xD;
             range may be retested. If the clinical values are outside the range on retesting, the&#xD;
             subject will not be eligible to participate in the study unless the clinical&#xD;
             investigator deems the result not to be significant.&#xD;
&#xD;
          -  Subjects who have a history of allergic responses to the class of drug being tested&#xD;
             will be excluded from the study.&#xD;
&#xD;
          -  All subjects will have urine samples assayed for the presence of drugs of abuse as&#xD;
             part of the clinical laboratory screening procedures and at each dosing period&#xD;
             check-in. Subjects found to have urine concentrations of any of the tested drugs will&#xD;
             not be allowed to participate.&#xD;
&#xD;
          -  Subjects should not have donated blood and/ot plasma for at least thirty (30) days&#xD;
             prior to the first dosing of the study.&#xD;
&#xD;
          -  Subjects who have taken any investigational drug within thirty (30) days prior to the&#xD;
             first dosing of the study will not be allowed to participate.&#xD;
&#xD;
          -  Female subjects who are pregnant, breast-feeding, or who are likely to become pregnant&#xD;
             during the study will not be allowed to participate. Female subjects of child bearing&#xD;
             potential must either abstain from sexual intercourse or use a reliable barrier method&#xD;
             (e.g. condom, IUD) of contraception during the course of the study (first dosing until&#xD;
             last blood collection) or they will not be allowed to participate. Subjects who have&#xD;
             used implanted or injected hormonal contraceptives anytime during the 180 days prior&#xD;
             to study dosing or oral hormonal contraceptives with in 14 days of dosing will not be&#xD;
             allowed to participate.&#xD;
&#xD;
          -  All female subjects will be screened for pregnancy at check-in each study period.&#xD;
             Subjects with positive or inconclusive results will be with drawn from the study.&#xD;
&#xD;
          -  Subjects who do not tolerate venipuncture will not be allowed to participate.&#xD;
&#xD;
          -  Subjects who use tobacco in any form will not be eligible to participate in the study.&#xD;
             Three months abstinence is required.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Herrmann, M.D.; Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gateway Medical Research, Inc.</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioassay Laboratory, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <last_update_submitted>February 2, 2009</last_update_submitted>
  <last_update_submitted_qc>February 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 2, 2009</submitted>
    <returned>August 17, 2009</returned>
    <submitted>September 11, 2009</submitted>
    <returned>October 14, 2009</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

